DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award
ID: 358720Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358720
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) for fiscal year 2025. This grant aims to support the development and validation of clinical outcomes and biomarkers specifically for enhancing clinical trials in Amyotrophic Lateral Sclerosis (ALS), focusing on targeted therapies or genetic mutations rather than broad applicability to all patients. With an estimated total program funding of $6.2 million, the program anticipates awarding approximately five grants, each with a maximum budget of $750,000 for a duration of up to three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    A03.pdf
    The Department of Defense's Amyotrophic Lateral Sclerosis Research Program (ALSRP) invites applications for the Clinical Outcomes and Biomarkers Award (COBA) for fiscal year 2025. This funding opportunity aims to support research focused on developing and validating clinical outcomes and biomarkers to enhance ALS clinical trials, targeting specific therapies or genetic mutations without needing broad applicability to all patients. Approximately $6.2 million is allocated to fund around five awards, with a maximum budget of $750,000 for a period of up to three years. Eligible applicants include both domestic and foreign organizations, academic institutions, and non-profit entities. Independent investigators at all career levels can serve as Principal Investigators. The application process includes a two-step submission: a pre-application due by June 6, 2025, and a full application due by August 27, 2025. Key focus areas include identifying clinical biomarkers for ALS and developing outcome measures that could impact clinical trial success. The proposal must incorporate community collaboration, emphasizing the involvement of patients and caregivers to ensure research relevance. Applications should detail plans for data sharing and resource utilization, aligning with regulatory considerations for ALS therapy development. The review process comprises preliminary screenings and comprehensive assessments evaluating scientific merit and relevance to the program’s objectives.
    Similar Opportunities
    DOD Amyotrophic Lateral Sclerosis, Pilot Clinical Trial Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award to support clinical trials aimed at improving the treatment and management of Amyotrophic Lateral Sclerosis (ALS). Applicants are required to focus on either biomarker-driven interventions or enhancements in clinical care, with an emphasis on incorporating community collaboration to optimize research impact. This funding opportunity allocates approximately $6.6 million to support around two pilot clinical trial applications, with a direct cost cap of $2 million for each project. Interested parties must submit a pre-application by June 6, 2025, followed by a full application due on August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) to support innovative research aimed at developing therapies for Amyotrophic Lateral Sclerosis (ALS). This grant program seeks applications that demonstrate proof-of-concept efficacy in preclinical models of ALS, with a focus on empirical therapeutic studies and the development of mechanism-specific biomarkers to enhance trial design and patient selection. With an estimated total funding of approximately $9.8 million, the program anticipates awarding about four grants, each capped at $1.5 million for a maximum duration of three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Therapeutic Idea Award (TIA) under the fiscal year 2025 Amyotrophic Lateral Sclerosis Research Program (ALSRP). This grant aims to support innovative, high-risk research proposals focused on drug or therapy development for Amyotrophic Lateral Sclerosis (ALS), with an emphasis on generating preliminary data for future therapeutic investigations. The program has a total funding amount of approximately $10.8 million, with individual awards capped at $600,000 and a performance period not exceeding two years. Interested applicants must submit pre-applications by June 6, 2025, and full applications by August 27, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Alzheimer’s Research Program Transforming Care Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Care Award to support innovative clinical research aimed at improving care for individuals with Alzheimer's disease and related dementias (AD/ADRD). This funding opportunity encourages community collaboration and requires projects to focus on interventions that enhance the quality of life for both patients and their caregivers. Approximately $5.2 million is available to fund around three awards, with pre-applications due by June 12, 2025, and full applications due by August 29, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Alzheimer’s Research Program Transforming Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Research Award to support innovative research aimed at reducing the risk of Alzheimer's disease and related dementias (AD/ADRD). This grant opportunity encourages diverse applicants, including for-profit, non-profit, and academic institutions, and emphasizes the necessity of community collaboration, particularly for clinical research projects. With an estimated total program funding of $4 million, the program anticipates awarding approximately four grants, each providing up to $1 million over a maximum of three years. Interested applicants must submit a pre-application by June 12, 2025, followed by a full application due by August 29, 2025. For further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Alzheimer’s Research Program Transforming Diagnosis Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Diagnosis Award to support innovative research aimed at enhancing the diagnosis and prognosis of Alzheimer's disease and related dementias (AD/ADRD). This grant opportunity encourages community collaboration and requires the submission of preliminary data, with a focus on addressing barriers to effective dementia diagnosis. With an estimated total program funding of $3.2 million, the program anticipates awarding two grants, with funding caps set at $1.5 million for single Principal Investigator (PI) proposals and $1.7 million for those utilizing the Career Initiation or Transition Partnership Option. Interested applicants must submit a pre-application by June 12, 2025, followed by a full application due by August 29, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Duchenne Muscular Dystrophy, Clinical/Translational Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity for the Duchenne Muscular Dystrophy Research Program's Clinical/Translational Research Award (CTRA) for fiscal year 2025. This funding initiative aims to support advanced translational research that accelerates promising ideas in Duchenne muscular dystrophy (DMD) into clinical applications, particularly focusing on therapies effective across all age groups, including infants and nonambulatory individuals. With an estimated total program funding of approximately $8.56 million, the program anticipates awarding around five grants, encouraging collaborations with early-career investigators and requiring applications to include preliminary data relevant to DMD. Interested applicants should note that a pre-application is due by July 25, 2025, with full applications due by August 8, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Peer Reviewed Medical Research Program, Clinical Trial Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity under the Peer Reviewed Medical Research Program (PRMRP) for the fiscal year 2025, specifically for the Clinical Trial Award (CTA). This program aims to support the rapid implementation of clinical trials that can significantly impact the treatment or management of diseases relevant to military health, with a focus on areas such as autoimmune disorders, cardiovascular health, infectious diseases, and neuroscience. Approximately $32 million is available for this initiative, with an expected four awards, each capped at $8 million, and applications are due by July 21, 2025. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    DOD Duchenne Muscular Dystrophy, Idea Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA), is offering the Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) for fiscal year 2025. This grant aims to support innovative, high-risk research that seeks to improve outcomes for individuals with Duchenne muscular dystrophy (DMD), encouraging applications that present well-formulated hypotheses based on solid scientific rationale. The program is particularly focused on studies targeting the primary pathology of DMD and emphasizes collaboration among experienced researchers, while excluding clinical trials in favor of fundamental and preparatory research. The total funding available is approximately $1.68 million, with up to three awards capped at $350,000 each for direct costs over a maximum of two years. Interested applicants must submit a pre-application by July 2025, followed by a full application by August 2025, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    Studies Addressing Rare Neurodegenerative Diseases including ALS
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for studies addressing rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). This grant aims to support research that advances the development of medical products intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in both adults and children. The initiative is crucial for addressing significant knowledge gaps in the field and is expected to have a substantial impact on the development of interventions for these conditions. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610 for further information. The FDA anticipates awarding approximately 10 grants in fiscal year 2025, with no cost-sharing or matching requirements.